225 related articles for article (PubMed ID: 25562555)
1. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study.
Klimek L; Bachert C; Mösges R; Munzel U; Price D; Virchow JC; Wahn U; Bousquet J
Allergy Asthma Proc; 2015; 36(1):40-7. PubMed ID: 25562555
[TBL] [Abstract][Full Text] [Related]
2. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
Meltzer EO; LaForce C; Ratner P; Price D; Ginsberg D; Carr W
Allergy Asthma Proc; 2012; 33(4):324-32. PubMed ID: 22856633
[TBL] [Abstract][Full Text] [Related]
3. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U
Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
Klimek L; Bousquet J; Price D
Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312
[TBL] [Abstract][Full Text] [Related]
5. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark.
Haahr PA; Jacobsen C; Christensen ME
Int Forum Allergy Rhinol; 2019 Apr; 9(4):388-395. PubMed ID: 30659752
[TBL] [Abstract][Full Text] [Related]
6. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
Carr W; Bernstein J; Lieberman P; Meltzer E; Bachert C; Price D; Munzel U; Bousquet J
J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065
[TBL] [Abstract][Full Text] [Related]
7. MP29-02: a breakthrough for the treatment of allergic rhinitis.
Bernstein JA
Expert Opin Pharmacother; 2013 Oct; 14(15):2101-13. PubMed ID: 23977840
[TBL] [Abstract][Full Text] [Related]
8. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
Price D; Shah S; Bhatia S; Bachert C; Berger W; Bousquet J; Carr W; Hellings P; Munzel U; Scadding G; Lieberman P
J Investig Allergol Clin Immunol; 2013; 23(7):495-503. PubMed ID: 24654314
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
Meltzer E; Ratner P; Bachert C; Carr W; Berger W; Canonica GW; Hadley J; Lieberman P; Hampel FC; Mullol J; Munzel U; Price D; Scadding G; Virchow JC; Wahn U; Murray R; Bousquet J
Int Arch Allergy Immunol; 2013; 161(4):369-77. PubMed ID: 23652808
[TBL] [Abstract][Full Text] [Related]
10. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania.
Agache I; Doros IC; Leru PM; Bucur I; Poenaru M; Sarafoleanu C
Rhinology; 2018 Mar; 56(1):33-41. PubMed ID: 28942457
[TBL] [Abstract][Full Text] [Related]
11. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study.
Klimek L; Bachert C; Stjärne P; Dollner R; Larsen P; Haahr P; Agache I; Scadding G; Price D
Allergy Asthma Proc; 2016 Sep; 37(5):376-86. PubMed ID: 27657521
[TBL] [Abstract][Full Text] [Related]
12. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
Berger WE; Shah S; Lieberman P; Hadley J; Price D; Munzel U; Bhatia S
J Allergy Clin Immunol Pract; 2014; 2(2):179-85. PubMed ID: 24607046
[TBL] [Abstract][Full Text] [Related]
13. Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study.
Klimek L; Price D; Gálffy G; Emmeluth M; Koltun A; Kopietz F; Nguyen DT; van Weissenbruch R; Pohl W; Kuhl HC; Scadding G; Mullol J
Int Arch Allergy Immunol; 2020; 181(10):754-764. PubMed ID: 32829329
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C
Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291
[TBL] [Abstract][Full Text] [Related]
15. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy.
Kaulsay R; Nguyen DT; Kuhl HC
Immun Inflamm Dis; 2018 Dec; 6(4):456-464. PubMed ID: 30306729
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
Derendorf H; Munzel U; Petzold U; Maus J; Mascher H; Hermann R; Bousquet J
Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
[TBL] [Abstract][Full Text] [Related]
17. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort.
Stjarne P; Strand V; Theman K; Ehnhage A
Rhinology; 2019 Aug; 57(4):279-286. PubMed ID: 30938376
[TBL] [Abstract][Full Text] [Related]
18. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
[TBL] [Abstract][Full Text] [Related]
19. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
Kortekaas Krohn I; Callebaut I; Alpizar YA; Steelant B; Van Gerven L; Skov PS; Kasran A; Talavera K; Wouters MM; Ceuppens JL; Seys SF; Hellings PW
Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
Derendorf H; Meltzer EO; Hermann R; Canonica GW
Drugs Today (Barc); 2014 Jan; 50(1):15-31. PubMed ID: 24524103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]